GLA
RCUS icon

Great Lakes Advisors’s Arcus Biosciences RCUS Stock Holding History

Great Lakes Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-194,810
Closed -$5.06M – 727
2020
Q4 		$5.06M Buy
+194,810
New +$4.72M 0.09% 248

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Great Lakes Advisors's RCUS Position: Q1 2021 in Review

Great Lakes Advisors sold out of Arcus Biosciences (RCUS) in Q1 2021, closing a stake of 194,810 shares — an estimated $5.06M sold.

Great Lakes Advisors first reported a position in RCUS in Q4 2020 and held it in 1 quarter. The position peaked at $5.06M in Q4 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q1 2021.

  • Great Lakes Advisors reported no remaining Arcus Biosciences position as of Q1 2021 after selling out during the quarter.
  • Great Lakes Advisors sold 194,810 Arcus Biosciences shares in Q1 2021, an estimated $5.06M.
  • Great Lakes Advisors first reported a position in Arcus Biosciences in Q4 2020 and held it in 1 quarter.
  • Great Lakes Advisors's Arcus Biosciences position peaked at $5.06M in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2021.

Based on Great Lakes Advisors's 13F filing for Q1 2021, filed 3 May 2021.